ImmunoGen Inc. (NASDAQ:IMGN) CEO Mark J. Enyedy acquired 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 8th. The stock was bought at an average price of $1.83 per share, with a total value of $45,750.00. Following the transaction, the chief executive officer now directly owns 100,100 shares in the company, valued at $183,183. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

ImmunoGen Inc. (NASDAQ:IMGN) opened at 2.15 on Friday. The stock’s 50 day moving average is $2.29 and its 200-day moving average is $3.57. The firm’s market capitalization is $187.27 million. ImmunoGen Inc. has a 1-year low of $1.51 and a 1-year high of $14.22.

ImmunoGen (NASDAQ:IMGN) last issued its quarterly earnings results on Friday, October 28th. The biotechnology company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by $0.13. The firm had revenue of $7.66 million for the quarter, compared to the consensus estimate of $21.12 million. The business’s revenue for the quarter was down 48.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.39) EPS. Analysts forecast that ImmunoGen Inc. will post ($1.67) EPS for the current year.

Insider Buying and Selling by Quarter for ImmunoGen (NASDAQ:IMGN)

Several research analysts recently weighed in on IMGN shares. Zacks Investment Research upgraded shares of ImmunoGen from a “sell” rating to a “hold” rating in a research report on Wednesday, October 19th. Canaccord Genuity set a $6.00 target price on shares of ImmunoGen and gave the company a “buy” rating in a research report on Friday, October 28th. JPMorgan Chase & Co. set a $5.00 target price on shares of ImmunoGen and gave the company a “hold” rating in a research report on Friday, August 5th. Jefferies Group reiterated a “buy” rating and set a $6.00 target price (down previously from $13.00) on shares of ImmunoGen in a research report on Friday, August 5th. Finally, Cantor Fitzgerald set a $5.00 target price on shares of ImmunoGen and gave the company a “hold” rating in a research report on Sunday, October 30th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $6.69.

Institutional investors have recently modified their holdings of the company. California State Teachers Retirement System raised its position in shares of ImmunoGen by 0.7% in the third quarter. California State Teachers Retirement System now owns 177,850 shares of the biotechnology company’s stock worth $477,000 after buying an additional 1,200 shares during the period. BlackRock Institutional Trust Company N.A. raised its position in shares of ImmunoGen by 1.1% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 2,127,680 shares of the biotechnology company’s stock worth $5,702,000 after buying an additional 22,427 shares during the period. Teachers Advisors LLC raised its position in shares of ImmunoGen by 47.9% in the third quarter. Teachers Advisors LLC now owns 189,688 shares of the biotechnology company’s stock worth $508,000 after buying an additional 61,416 shares during the period. BlackRock Fund Advisors raised its position in shares of ImmunoGen by 6.4% in the third quarter. BlackRock Fund Advisors now owns 3,310,737 shares of the biotechnology company’s stock worth $8,873,000 after buying an additional 199,247 shares during the period. Finally, KBC Group NV acquired a new position in shares of ImmunoGen during the third quarter worth approximately $585,000. Institutional investors own 91.63% of the company’s stock.

ImmunoGen Company Profile

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

5 Day Chart for NASDAQ:IMGN

Receive News & Stock Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related stocks with our FREE daily email newsletter.